Navigation Links
Transcriptase in Biological Technology

Ardea to Present Data on Lead HIV Candidate, RDEA806, at XVII International AIDS Conference

... novel investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for patients with human ... of RDEA806, a novel HIV non-nucleoside reverse transcriptase inhibitor, in treatment of naive HIV patients" ... is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which has successfully ...

Ardea Biosciences to Present Preclinical Data on Three HIV Non-Nucleoside Reverse Transcriptase Inhibitors During 15th Annual Conference on Retroviruses and Opportunistic Infections

... data on the Company's non-nucleoside reverse transcriptase inhibitor (NNRTI) family of compounds, including ... RDEA806 is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) for the potential treatment of ... candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study ...

Ardea to Present Data on Lead HIV Candidate, RDEA806, at ICAAC/IDSA Joint Meeting

... Presentation Title: RDEA806, a Novel HIV Non-Nucleoside Reverse transcriptase Inhibitor, Shows Positive Outcome in Treatment of Naive HIV Patients ... most advanced development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which has successfully completed a Phase 2a study for ...

Ardea Biosciences Presents Inflammation Program Data for Arthritis and Gout at 2008 Annual European Congress of Rheumatology

... RDEA594 is a metabolite of RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI) in development for the treatment of HIV. In Phase 1 ... most advanced development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. ...

Ardea to Present Data on HIV Non-Nucleoside Reverse Transcriptase Inhibitor and Two MEK Inhibitors at Upcoming Medical Conferences

... data will be presented on its second generation non-nucleoside reverse transcriptase inhibitors (NNRTIs), at the 21st International Conference on Antiviral ... Our most advanced drug candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. ...

FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy

... INTELENCE (etravirine) tablets -- the first non-nucleoside reverse transcriptase inhibitor (NNRTI) to show antiviral activity in treatment- experienced ... that partially or completely stop the NNRTI from binding to the reverse transcriptase enzyme, causing the drug to lose effectiveness. As with other HIV ...

Ardea Biosciences, Inc. Reports Third Quarter 2007 Operating and Financial Results

... clinical studies of RDEA806, our lead non-nucleoside reverse transcriptase inhibitor (NNRTI) for HIV, in August of 2007; -- Presentation of four ... year. These include RDEA806, the Company's lead non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV, which recently completed Phase ...

A New Era in the Application of Lab-on-a-Chip to Rapid Point-of-Care Diagnosis

... capture (NASBA-EOC). The VDS technology has an advantage of not requiring the use of specialized equipment; VetDetect utilizes real-time reverse transcriptase polymerase chain reaction (RT-PCR) and VetScreen employs the conventional gel-based RT-PCR technique. All three platforms are highly sensitive and ...

Mylan's Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R)

... Tablets are the generic version of Gilead Sciences Inc.'s Truvada(R) Tablets. Truvada(R) is a second-line anti-HIV drug in the nucleoside reverse transcriptase inhibitor (NRTI or "nuke") family and is used in combination with other medications to control HIV infection. Patients often use second-line ...

Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results

... Business Highlights Idenix successfully completed a phase I/II proof-of-concept study of IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of human immunodeficiency virus (HIV) in September 2008. In February 2009, the company announced that it had ...

Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results

... approximately $60.1 million. 2008 Year-to-Date Business Highlights -- Idenix completed its phase I/II study of IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed for the treatment of HIV-1, which demonstrated potent antiviral activity at all doses tested. Patients receiving ...

Ardea Biosciences to Present at the UBS Global Life Sciences Conference and the Third Annual JMP Securities Healthcare Focus Conference

... in clinical trials and others in preclinical development and discovery. Our most advanced product candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which has successfully completed a Phase 2a study for the treatment of patients with HIV. We have evaluated our second-generation ...

Ardea Biosciences to Present Data on Gout and Inflammation Programs at the 2008 ACR/ARHP Annual Scientific Meeting

... in clinical trials and others in preclinical development and discovery. Our most advanced product candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which has successfully completed a Phase 2a study for the treatment of patients with HIV. We have evaluated our second-generation ...

Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium

... in clinical trials and others in preclinical development and discovery. Our most advanced product candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which has successfully completed a Phase 2a study for the treatment of patients with HIV. We have evaluated our second-generation ...

ImQuest Receives $6.4 M Five Year Award from NIH to Develop Long-Lasting Combination Topical Microbicides To Prevent HIV Transmission

... cells, preventing infection. Finally, the third and most potent activity of the product will prevent the critical action of the virus-encoded reverse transcriptase inside the cell. Key features of the development program include the formulation of the product for delivery as gels or intravaginal rings, ...

Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results

... 2008 Year-to-Date Business Highlights -- Idenix has reported positive data from an ongoing phase I/II study of IDX899, a non-nucleoside reverse transcriptase inhibitor (NNRTI) being developed for the treatment of HIV-1. Patients receiving once-daily IDX899 achieved a mean plasma viral load reduction of ...

Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout

... in clinical trials and others in preclinical development and discovery. Our most advanced development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which has successfully completed a Phase 2a study for the treatment of patients with HIV. We have evaluated our ...

Craig Johnson Joins Ardea Biosciences' Board of Directors

... in clinical trials and others in preclinical development and discovery. Our most advanced development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. We have evaluated our second-generation NNRTI for the treatment of HIV, ...

Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at Digestive Disease Week 2008

... in clinical trials and several others in preclinical development and discovery. Our most advanced drug candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. We have evaluated our second generation NNRTI, RDEA427, for the treatment ...

Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company

... in the first quarter of 2008 from $120 million in the same period in 2007. -- Sales of the SUSTIVA(R) Franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV, increased 21% to $273 million in the first quarter of 2008 from $226 million in the same period in 2007. ...

Ardea Presents Preclinical Data on Novel Next Generation Non-Nucleoside Reverse Transcriptase Inhibitors Demonstrating Potent Anti-HIV Activity Against Resistant Viruses

... "A Novel NNRTI Class with Potent Anti-HIV Activity against NNRTI-Resistant Viruses." About RDEA806 RDEA806 is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) for the potential treatment of HIV infection. Based on preclinical and clinical studies to-date, Ardea believes that RDEA806 may ...

Ardea to Present at Cowen and Company's 28th Annual Health Care Conference

... development and several others in preclinical development. Ardea's most advanced clinical development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. In addition, the Company is investigating RDEA806 for the treatment of ....

Monogram Biosciences and Avexa Announce Exclusive Collaboration to Support New HIV Drug Discovery and Development Efforts

... across its virology portfolio, including the phase III program for its lead compound, apricitabine (ATC), an anti-HIV drug in the nucleoside reverse transcriptase inhibitor (NRTI) class. ATC has successfully completed the 48 week dosing of its Phase 2b trial and the Phase 3 program has been initiated. Avexa ...

Ardea Biosciences to Move Headquarters and R&D Laboratories to San Diego

... development and several others in preclinical development. Ardea's most advanced clinical development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. In addition, the Company is investigating RDEA806 for the treatment of ....

Ardea Biosciences Establishes Scientific Advisory Board for Inflammation Program

... development and several others in preclinical development. Ardea's most advanced clinical development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. In addition, the Company is investigating RDEA806 for the treatment of ....

Ardea Biosciences to Present at Roth Capital Partners' 20th Annual OC Growth Stock Conference

... development and several others in preclinical development. Ardea's most advanced clinical development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. In addition, the Company is also investigating RDEA806 for the treatment of ...

Ardea Biosciences Establishes Scientific Advisory Board for HIV Program

... development and several others in preclinical development. Ardea's most advanced clinical development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for the treatment of HIV. In addition, the Company is also investigating RDEA806 for the treatment of ...

Ardea Biosciences Announces $40 Million Private Placement

... planned for the first half of 2008. Ardea's most advanced clinical development programs include: RDEA806, the Company's lead non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV, which is expected to enter a Phase 2a clinical trial in the fourth quarter of 2007; RDEA119, a ...

Ardea Biosciences to Participate in RBC Capital Markets 2007 Healthcare Conference

... planned for the first half of 2008. Ardea's most advanced clinical development programs include: RDEA806, the Company's lead non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV, which is expected to enter a Phase 2a clinical trial in the fourth quarter of 2007; RDEA119, a ...

New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor Properties

... The Company plans to initiate clinical studies on four compounds this year. These include RDEA806, the Company's lead non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV, which recently completed Phase 1 clinical trials, RDEA119, a mitogen-activated ERK kinase (MEK) inhibitor ...

Ardea Biosciences Announces Changes to Research Management

... The Company plans to initiate clinical studies on four compounds this year. These include RDEA806, the Company's lead non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV, which recently completed Phase 1 clinical trials, RDEA119, a mitogen-activated ERK kinase (MEK) inhibitor ...

Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs

... on what we believe is most critical to our future success -- building and advancing our pipeline." Idenix currently has a non-nucleoside reverse transcriptase inhibitor (NNRTI), IDX899, for the treatment of HIV-1 that is being evaluated in phase I/II clinical testing. The company also has a comprehensive ...

Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.

... on three or more compounds this year. These compounds include RDEA806 and lead compounds from our 900 series, which are non-nucleoside reverse transcriptase inhibitors (NNRTIs) for the treatment of HIV, and RDEA119, a mitogen-activated ERK kinase (MEK) inhibitor for the treatment of cancer and ...

RNA Amplification Just Got Better: MessageAmp II

... , an M-MLV reverse transcriptase specifically engineered to ... Figure 1. ArrayScript Reverse transcriptase Synthesizes Intact cDNA Products as ... Figure 2. ArrayScript Reverse transcriptase Produces up to Twice the aRNA Yield in MessageAmp ...

ArrayScript RT: Maximize Yields of Full-length cDNA

... have engineered a mutant form of M-MLV reverse transcriptase to improve production of full-length ... Figure 1. ArrayScript Reverse transcriptase Synthesizes Intact cDNA Products as ... Figure 2. ArrayScript Reverse transcriptase Produces up to Twice the cRNA Yield in ...

Use of Transcriptor Reverse Transcriptase in Microarray Analysis

... intensities shows that the Transcriptor Reverse transcriptase produced a major shift in the signal distribution ... that target labelling with Transcriptor Reverse transcriptase is highly reproducible and produces fewer outlier ... properties of Transcriptor Reverse transcriptase suggest that it will produce a labelled target ...

Increase the Power and Sensitivity for Your cDNA Synthesis with the New Transcriptor Reverse Transcriptase

... Transcriptor Reverse transcriptase is a new recombinant reverse transcriptase (RT) expressed in E. coli. The enzyme has ... Transcriptor Reverse transcriptase has a broad dynamic detection range of 12 1.2 x ...

Transcriptor Reverse Transcriptase

... with the new Transcriptor Reverse transcriptase With the new ... RNA Transcriptor Reverse transcriptase is the product of choice to transcribe RNA ... inserts Transcriptor Reverse transcriptase will allow you to Get ...

RT-PCR procedures

... In the first step, reverse transcriptase produces first-strand cDNA in the ... the right combination of reverse transcriptase and thermostable DNA polymerase, two-step ... Finally, the thermoactive reverse transcriptase used in this procedure allow a high RT ...
Other Contents
(Date:12/11/2014)... Dec. 09, 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the ... APAC Region 2015-2019"  report to their offering. ... market is advances in technology. With continuous advances ... solutions to the latest standard that meets the ...
(Date:12/10/2014)... , Dec. 8, 2014 You,ve been here ... account but can,t remember your password, site key or the ... was your first grade teacher? Today, ... the app that will finally put an end to ... 1U TM . 1U leverages a user,s smartphone ...
(Date:12/10/2014)... , Dec. 08, 2014 Research and ... the addition of the "Biometrics Market in ... http://photos.prnewswire.com/prnh/20130307/600769 ... projects such as rural banking and upgradation of ... trends witnessed in the market. Besides the aforementioned ...
Breaking Biology News(10 mins):Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 2The Password is Finally Dead: Launch of 1U Mobile App Eliminates Need for All Usernames and Passwords 3Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
(Date:12/22/2014)... St. Petersburg, FL (PRWEB) December 22, 2014 ... needed. Sublime Beauty® has a fast and easy solution that ... online gift cards can be purchased from from $25 up ... ®. "We offer 100% customer satisfaction and a wide array ... cards have no fees and no expiration dates. , ...
(Date:12/22/2014)... 22, 2014 NAPW honors ... Woman of the Year. She is recognized with this ... most recognized networking organization of professional women in the ... Association of Professional Women is a vibrant networking community ... , Ms. Kreider is passionate and committed to best ...
(Date:12/22/2014)... Washington, DC (PRWEB) December 22, 2014 ... begins its year-long, professional development programs this month. ... LEAD, which focuses on nurse educators fast-tracked for ... for the Leadership Development Program for Simulation Educators, ... that specialized area of nursing education. , ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 Parker & ... absolute best in Arizona home contracting services reports a ... to its quality services in 2014. As a company ... the early 1970s, Parker and Sons is a business ... The company works side-by-side with other top quality companies ...
(Date:12/21/2014)... (PRWEB) December 22, 2014 Recently, BambooFlooringChina.com, ... durable strand woven bamboo flooring collection , and launched ... 25%. The promotion is valid until Jan. 30, 2015. ... woven bamboo is the hardest bamboo flooring available today; ... resembling that of traditional teak hardwoods. Strand woven bamboo ...
Breaking Medicine News(10 mins):Health News:National Association of Professional Women Announces Cheryl A. Kreider, President / CEO of Kreider Health Solutions, LLC, a 2014 Professional Woman of the Year 2Health News:NLN Leadership Institute Announces 2015 Cohorts 2Health News:NLN Leadership Institute Announces 2015 Cohorts 3Health News:Parker & Sons Reports A Record Number Of Favorable References With Regard To Its Quality Services In 2014 2Health News:Parker & Sons Reports A Record Number Of Favorable References With Regard To Its Quality Services In 2014 3Health News:BambooFlooringChina.com Announced Its Durable Strand Woven Bamboo Flooring Collection 2
Other TagsOther Tags